{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T15:52:37Z","timestamp":1772034757752,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04748-z","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T14:57:08Z","timestamp":1757084228000},"page":"989-997","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of SGLT-2i and GLP-1RA on cardiovascular and renal outcomes in elderly patients with T2DM: a single-center retrospective cohort study"],"prefix":"10.1007","volume":"58","author":[{"given":"Yawei","family":"Qin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xvguang","family":"Xv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"key":"4748_CR1","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/S0140-6736(22)01655-5","volume":"400","author":"E Ahmad","year":"2022","unstructured":"Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ (2022) Type 2 diabetes. Lancet 400:1803\u20131820","journal-title":"Lancet"},{"key":"4748_CR2","doi-asserted-by":"publisher","first-page":"719","DOI":"10.4093\/dmj.2023.0112","volume":"47","author":"J Mesinovic","year":"2023","unstructured":"Mesinovic J, Fyfe JJ, Talevski J, Wheeler MJ, Leung GKW, George ES et al (2023) Type 2 diabetes mellitus and sarcopenia as comorbid chronic diseases in older adults: established and emerging treatments and therapies. Diabetes Metab J 47:719\u2013742","journal-title":"Diabetes Metab J"},{"key":"4748_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/nu13010183","author":"A Izzo","year":"2021","unstructured":"Izzo A, Massimino E, Riccardi G, Della Pepa G (2021) A narrative review on sarcopenia in type 2 diabetes mellitus: prevalence and associated factors. Nutrients. https:\/\/doi.org\/10.3390\/nu13010183","journal-title":"Nutrients"},{"key":"4748_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1556\/2060.2024.00317","volume":"111","author":"K Gado","year":"2024","unstructured":"Gado K, Tabak GA, Vingender I, Domjan G, Dornyei G (2024) Treatment of type 2 diabetes mellitus in the elderly\u2014special considerations. Physiol Int 111:143\u2013164","journal-title":"Physiol Int"},{"key":"4748_CR5","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41574-021-00512-2","volume":"17","author":"S Bellary","year":"2021","unstructured":"Bellary S, Kyrou I, Brown JE, Bailey CJ (2021) Type 2 diabetes mellitus in older adults: clinical considerations and management. Nat Rev Endocrinol 17:534\u2013548","journal-title":"Nat Rev Endocrinol"},{"key":"4748_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.49856","volume":"6","author":"S Bea","year":"2023","unstructured":"Bea S, Jeong HE, Filion KB, Yu OH, Cho YM, Lee BH et al (2023) Outcomes of SGLT-2i and GLP-1RA therapy among patients with type 2 diabetes and varying NAFLD status. JAMA Netw Open 6:e2349856","journal-title":"JAMA Netw Open"},{"key":"4748_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12933-023-02118-6","volume":"23","author":"R Marfella","year":"2024","unstructured":"Marfella R, Prattichizzo F, Sardu C, Rambaldi PF, Fumagalli C, Marfella LV et al (2024) GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes. Cardiovasc Diabetol 23:10","journal-title":"Cardiovasc Diabetol"},{"key":"4748_CR8","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.pcd.2022.03.012","volume":"16","author":"BM Mishriky","year":"2022","unstructured":"Mishriky BM, Cummings DM, Powell JR (2022) Cardiovascular benefits of GLP-1RA and SGLT-2i in women with type 2 diabetes. Prim Care Diabetes 16:471\u2013473","journal-title":"Prim Care Diabetes"},{"key":"4748_CR9","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.jacc.2024.06.016","volume":"84","author":"D Edmonston","year":"2024","unstructured":"Edmonston D, Mulder H, Lydon E, Chiswell K, Lampron Z, Shay C et al (2024) Kidney and cardiovascular effectiveness of SGLT2 inhibitors vs GLP-1 receptor agonists in type 2 diabetes. J Am Coll Cardiol 84:696\u2013708","journal-title":"J Am Coll Cardiol"},{"key":"4748_CR10","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","volume":"12","author":"EM Apperloo","year":"2024","unstructured":"Apperloo EM, Neuen BL, Fletcher RA, Jongs N, Anker SD, Bhatt DL et al (2024) Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 12:545\u2013557","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4748_CR11","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.2147\/DMSO.S425642","volume":"16","author":"J Xiang","year":"2023","unstructured":"Xiang J, Qin L, Zhong J, Xia N, Liang Y (2023) GLP-1RA liraglutide and semaglutide improves obesity-induced muscle atrophy via SIRT1 pathway. Diabetes Metab Syndr Obes 16:2433\u20132446","journal-title":"Diabetes Metab Syndr Obes"},{"key":"4748_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2023.112029","volume":"577","author":"J Shang","year":"2023","unstructured":"Shang J, Yan W, Cui X, Ma W, Wang Z, Liu N et al (2023) Schisandrin B, a potential GLP-1R agonist, exerts anti-diabetic effects by stimulating insulin secretion. Mol Cell Endocrinol 577:112029","journal-title":"Mol Cell Endocrinol"},{"key":"4748_CR13","doi-asserted-by":"crossref","first-page":"672","DOI":"10.2337\/db25-0282","volume":"74","author":"Y Wang","year":"2025","unstructured":"Wang Y, Xia C, Li M, Xu G (2025) Comparison of the effects of SGLT-2i versus GLP-1RA on cardiovascular and renal outcomes in patients with type 2 diabetes, based on baseline renal function. Diabetes 74:672\u2013681","journal-title":"Diabetes"},{"key":"4748_CR14","volume":"82","author":"V Kosjerina","year":"2025","unstructured":"Kosjerina V, Parsa M, Scheuer SH, Ankarfeldt MZ, Sorensen KK, Brock B et al (2025) Comparative cardiovascular effectiveness of newer glucose-lowering drugs in elderly with type 2 diabetes: a target trial emulation cohort study. EClinMed 82:103162","journal-title":"EClinMed"},{"key":"4748_CR15","first-page":"12","volume":"61","author":"Chinese Elderly Type 2 Diabetes P","year":"2022","unstructured":"Chinese Elderly Type 2 Diabetes P, Treatment of Clinical Guidelines Writing G, Geriatric E, Metabolism Branch of Chinese Geriatric S, Geriatric E, Metabolism Branch of Chinese Geriatric Health Care S, Chinese Elderly Type 2 Diabetes Prevention and Treatment of Clinical Guidelines Writing Group, Geriatric Endocrinology and Metabolism Branch of Chinese Geriatric Society, Geriatric Endocrinology and Metabolism Branch of Chinese Geriatric Health Care Society, Geriatric Professional Committee of Beijing Medical Award Foundation, National Clinical Medical Research Center for Geriatric Diseases (PLA General Hospital) (2022) Clinical guidelines for prevention and treatment of type 2 diabetes mellitus in the elderly in China (2022 edition). Zhonghua Nei Ke Za Zhi 61:12\u201350","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"4748_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154218","volume":"107","author":"N Katsiki","year":"2020","unstructured":"Katsiki N, Ferrannini E, Mantzoros C (2020) New American Diabetes Association (ADA)\/European Association for the Study of Diabetes (EASD) guidelines for the pharmacotherapy of type 2 diabetes: placing them into a practicing physician\u2019s perspective. Metabolism 107:154218","journal-title":"Metabolism"},{"key":"4748_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S2213-8587(20)30343-0","volume":"9","author":"N Marx","year":"2021","unstructured":"Marx N, Davies MJ, Grant PJ, Mathieu C, Petrie JR, Cosentino F et al (2021) Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. Lancet Diabetes Endocrinol 9:46\u201352","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4748_CR18","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1093\/eurjpc\/zwac315","volume":"30","author":"CE Lim","year":"2023","unstructured":"Lim CE, Pasternak B, Eliasson B, Danaei G, Ueda P (2023) Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA\/EASD consensus report in a national population of patients with type 2 diabetes. Eur J Prev Cardiol 30:634\u2013643","journal-title":"Eur J Prev Cardiol"},{"key":"4748_CR19","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","volume":"15","author":"KG Alberti","year":"1998","unstructured":"Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539\u2013553","journal-title":"Diabet Med"},{"key":"4748_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.70069","volume":"17","author":"A Krishnan","year":"2025","unstructured":"Krishnan A, Schneider CV, Mukherjee D, Woreta TA, Alqahtani SA (2025) Adverse liver and renal outcomes after initiating SGLT-2i and GLP-1RA therapy among patients with diabetes and MASLD. J Diabetes 17:e70069","journal-title":"J Diabetes"},{"key":"4748_CR21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/nep.13839","volume":"26","author":"RA Scholtes","year":"2021","unstructured":"Scholtes RA, van Baar MJB, Kok MD, Bjornstad P, Cherney DZI, Joles JA et al (2021) Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: interaction with SGLT2 inhibitors. Nephrology 26:377\u2013390","journal-title":"Nephrology"},{"key":"4748_CR22","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.2147\/DMSO.S448670","volume":"17","author":"MB Omari","year":"2024","unstructured":"Omari MB, Naseri S, Hassan AJ (2024) Drug safety evaluation of sodium-glucose cotransporter 2 inhibitors in diabetic comorbid patients by review of systemic extraglycemic effects. Diabetes Metab Syndr Obes 17:1131\u20131141","journal-title":"Diabetes Metab Syndr Obes"},{"key":"4748_CR23","doi-asserted-by":"publisher","first-page":"1213473","DOI":"10.3389\/fimmu.2023.1213473","volume":"14","author":"ZC Dai","year":"2023","unstructured":"Dai ZC, Chen JX, Zou R, Liang XB, Tang JX, Yao CW (2023) Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease. Front Immunol 14:1213473","journal-title":"Front Immunol"},{"key":"4748_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078483","volume":"385","author":"EL Fu","year":"2024","unstructured":"Fu EL, Wexler DJ, Cromer SJ, Bykov K, Paik JM, Patorno E (2024) SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study. BMJ 385:e078483","journal-title":"BMJ"},{"key":"4748_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4573","volume":"372","author":"SC Palmer","year":"2021","unstructured":"Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q et al (2021) Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 372:m4573","journal-title":"BMJ"},{"key":"4748_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109146","volume":"183","author":"Y Kawai","year":"2022","unstructured":"Kawai Y, Uneda K, Yamada T, Kinguchi S, Kobayashi K, Azushima K et al (2022) Comparison of effects of SGLT-2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus patients with\/without albuminuria: a systematic review and network meta-analysis. Diabetes Res Clin Pract 183:109146","journal-title":"Diabetes Res Clin Pract"},{"key":"4748_CR27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12933-020-01197-z","volume":"20","author":"T Yamada","year":"2021","unstructured":"Yamada T, Wakabayashi M, Bhalla A, Chopra N, Miyashita H, Mikami T et al (2021) Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. Cardiovasc Diabetol 20:14","journal-title":"Cardiovasc Diabetol"},{"key":"4748_CR28","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12933-020-01071-y","volume":"19","author":"L Ni","year":"2020","unstructured":"Ni L, Yuan C, Chen G, Zhang C, Wu X (2020) SGLT2i: beyond the glucose-lowering effect. Cardiovasc Diabetol 19:98","journal-title":"Cardiovasc Diabetol"},{"key":"4748_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1307715","volume":"14","author":"ED Meregildo-Rodriguez","year":"2023","unstructured":"Meregildo-Rodriguez ED, Asmat-Rubio MG, Vasquez-Tirado GA (2023) SGLT-2 inhibitors and prevention of contrast-induced nephropathy in patients with diabetes undergoing coronary angiography and percutaneous coronary interventions: systematic review and meta-analysis. Front Endocrinol (Lausanne) 14:1307715","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4748_CR30","volume":"15","author":"D Shami","year":"2023","unstructured":"Shami D, Sousou JM, Batarseh E, Alazrai L (2023) The roles of glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT-2) inhibitors in decreasing the occurrence of adverse cardiorenal events in patients with type 2 diabetes. Cureus 15:e33484","journal-title":"Cureus"},{"key":"4748_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.825897","volume":"9","author":"T Liang","year":"2022","unstructured":"Liang T, Xie X, Wu L, Li L, Yang L, Gao H et al (2022) Comparative analysis of the efficacies of probiotic supplementation and glucose-lowering drugs for the treatment of type 2 diabetes: a systematic review and meta-analysis. Front Nutr 9:825897","journal-title":"Front Nutr"},{"key":"4748_CR32","doi-asserted-by":"crossref","unstructured":"Popoviciu MS, Paduraru L, Yahya G, Metwally K, Cavalu S (2023) Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials. Int J Mol Sci 24:10449.","DOI":"10.3390\/ijms241310449"},{"key":"4748_CR33","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.ajcnut.2023.04.017","volume":"118","author":"Y Liu","year":"2023","unstructured":"Liu Y, Ruan B, Jiang H, Le S, Liu Y, Ao X et al (2023) The weight-loss effect of GLP-1RAs glucagon-like peptide-1 receptor agonists in non-diabetic individuals with overweight or obesity: a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials. Am J Clin Nutr 118:614\u2013626","journal-title":"Am J Clin Nutr"},{"key":"4748_CR34","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1210\/clinem\/dgac704","volume":"108","author":"GD Dimitriadis","year":"2023","unstructured":"Dimitriadis GD, Lambadiari V (2023) GLP-1 receptor agonists and SGLT-2 inhibitors as adjuncts to insulin in type 1 diabetes: benefits and concerns. J Clin Endocrinol Metab 108:e52\u2013e53","journal-title":"J Clin Endocrinol Metab"},{"key":"4748_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1517272","volume":"16","author":"J Guo","year":"2025","unstructured":"Guo J, Wei M, Zhang W, Jiang Y, Li A, Wang C et al (2025) Clinical efficacy and safety of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, and finerenone in type 2 diabetes mellitus with non-dialysis chronic kidney disease: a network meta-analysis of randomized clinical trials. Front Pharmacol 16:1517272","journal-title":"Front Pharmacol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04748-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04748-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04748-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T14:30:42Z","timestamp":1772029842000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04748-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["4748"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04748-z","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,5]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The research plan was approved by the Academic Ethics Committee of The\nAffiliated Hospital of Xuzhou Medical University. All procedures were strictly implemented according to the\n                      Declaration of Helsinki\n                      .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent were gained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}